

氏名	所属	職名	取得学位	専門分野	主な論文・著作・業績
石河 太知	微生物学講座 分子微生物学分野	教授	博士（歯学）	口腔感染症学 細菌病原性 免疫応答	<p>①Ishikawa T, Sugawara S, Kihara H, hanasaka T, Hatakeyama W, Sasaki M and Kondo H: Titanium nanoparticles potentially affect gingival tissue through IL-13α2 receptor expression. Journal of oral science, 63(3) 263-266. (2021)</p> <p>②Ishikawa T, Terashima J, Sasaki D, Shimoyama Y, Yaegashi T and Sasaki M: Establishment and use of a three-dimensional ameloblastoma culture model to study the effects of butyric acid on the transcription of growth factors and laminin β3. Archives of Oral Biology, 21;118:104845 (2020)</p> <p>③Sjöqvist S, Ishikawa T, Shimura D, Kasai Y, Imafuku A, Bou-Ghannam S, Iwata T, Kanai N.: Exosomes derived from clinical-grade oral mucosal epithelial cell sheets promote wound healing. Journal of extracellular vesicles, 8(1), 1565264. (2019)</p> <p>④Ishikawa T, Wondimu Z, Oikawa Y, Ingerpuu S, Virtanen I and Patarroyo M: Monoclonal antibodies to human laminin α4 chain globular domain inhibit tumor cell adhesion and migration on laminin 411 and 421, and binding of α6β1 integrin and MCAM to α4-laminins. Matrix Biology, 36: 5-14 (2014)</p> <p>⑤文部科学省科学研究費補助金 基盤研究(C)「課題名：低体重出生に関わる苦味受容体を介した歯周病原細菌の影響」(2020-04-01 – 2024-03-31) 研究代表者</p>
三浦 利貴	微生物学講座 分子微生物学分野	助教	博士（薬学）	薬物動態学 口腔感染症学 エピゲノム	<p>①Habano W, Miura T, Terashima J and Ozawa S: Aryl hydrocarbon receptor as a DNA methylation reader in the stress response pathway. Toxicology, 470(30):153154 (2022)</p> <p>②Miura T, Onodera R, Terashima J, Ozawa S and Habano W: β-naphthoflavone-induced upregulation of CYP1B1 expression is mediated by the preferential binding of aryl hydrocarbon receptor to unmethylated xenobiotic responsive elements. Experimental and Therapeutic Medicine, 22(6):1410 (2021)</p> <p>③Ozawa S, Miura T, Terashima J, Habano W and Ishida S: Recent Progress in Prediction Systems for Drug-induced Liver Injury Using In vitro Cell Culture. Drug Metabolism Letters, 14(1) 25-40. (2021)</p> <p>④Ozawa S, Miura T, Terashima J and Habano W: Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review. Cancer Drug Resistance. 4:946-964. (2021)</p>